Skip to main content
Share On
Donation
Donation period
Choose an option
One-Time
Monthly
Secondary navigation
About Us
News
Events
Blogs
Advocacy
Fundraise
Search
Donate Now
Main navigation
What Is Multiple Myeloma?
Newly Diagnosed
Do You Have Myeloma?
Multiple Myeloma Diagnostic Criteria
MGUS, Smoldering Myeloma, and Myeloma
Types of Myeloma
Urgent Problems at Diagnosis
Is Multiple Myeloma Curable?
FAQ
Tests and Staging
What Tests Do You Need?
Tests to assess blood cells
Tests to assess kidney function
Tests to assess proteins and other substances in the blood
Tests to assess monoclonal protein
Bone marrow tests
Imaging studies
MRD and Mass Spectrometry Testing
Staging and Risk Stratification
International Staging System (ISS) and Revised ISS (R-ISS)
Treatment
What Are First-Line Treatments?
Role of Transplant
Role of Consolidation
Role of Maintenance/Continuous Therapy
What Is Relapse?
Multiple Myeloma Medications
ABECMA® (idecabtagene vicleucel)
AREDIA® (pamidronate disodium)
BLENREP (belantamab mafodotin-blmf)
CARVYKTI (ciltacabtagene autoleucel)
CYTOXAN® (cyclophosphamide)
DARZALEX® (daratumumab)
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)
Dexamethasone
EMPLICITI® (elotuzumab)
KYPROLIS® (carfilzomib)
Melphalan (ALKERAN®)
NINLARO® (ixazomib)
POMALYST® (pomalidomide)
REVLIMID® (lenalidomide)
Sarclisa (isatuximab-irfc)
TALVEY (talquetamab)
TECVAYLI (teclistamab-cqyv)
THALOMID® (thalidomide)
VELCADE® (bortezomib)
Xgeva (denosumab)
Xpovio (selinexor)
Zometa (zoledronic acid)
Side Effects Management
Anemia
Bone Disease
Distress, Fatigue, and Sexuality
Gastrointestinal Problems
Heart and Lung Complications
Kidney Failure
Myelosuppression
Pain Management
Palliative Care
Peripheral Neuropathy
Steroid Side Effects
Emerging Therapies
Immune Therapy
Clinical Trials
A Clinical Trials Glossary
Clinical Trials Fact Sheets
Long-Term Care Planning
Mobility and safety
Routine health maintenance
Publications and Videos
IMF Publications
Patient Handbook
Understanding Series
Myeloma Minute
Myeloma Today
Tip Cards
Foreign Language Resources
IMF Videos
Black Swan Research Initiative
IMWG Conference Series
Living Well With Myeloma
Patient and Family Seminars
Community Workshop
Nurse Leadership Board Series
Patient Stories - Podcasts
Myeloma Information
Healthcare Professional Resources
IMWG Publications
Nurse Leadership Board Summaries
ASH Abstract Summaries
ASCO Abstract Summaries
CME & Education
Doctors' Edition: Proteasome Inhibitors
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma
Resources and Support
IMF Support Network
Find a Support Group
Contact the InfoLine
Care Partner Resources
Find a Clinical Trial
Myeloma Knowledge Platform
Patient and Family Seminars
Myeloma Community Workshops
Weekly Newsletter
Mind and Body Wellness
The Patient Perspective at ASH
Diversity, Equity, and Inclusion
Disparities in Healthcare
Disparities in African Americans
Disparities in Hispanic Americans
Disparities in Other Races and Ethnicities in the U.S.
Disparities in Access to Clinical Trials and New Therapies
M-Power Initiative
External Resources
Drug Reimbursement and Co-Pay Assistance Resources
Financial Resources
Government Resources
Counseling and Support Resources
Housing and Travel Resources
International Support
Legal Resources
Pain Management Resources
Transplant Resources
Other Cancer Resources
Our Research
IMF Medical Research
Black Swan Research Initiative
Black Swan Research Projects
Black Swan Publications
Contact the Black Swan Research Initiative
International Myeloma Working Group
International Myeloma Working Group (IMWG) Publications
International Myeloma Working Group (IMWG) Conference Series
Asian Myeloma Network
Multiple Myeloma in Asia
Myeloma Clinical Trials in Asia
Latin American Myeloma Network
Road to the Cure
Nurse Leadership Board
Nurse Leadership Board Members
Nurse Leadership Board Publications
Nursing Resources
Myeloma University
IMF Research Awards
Kyle Lifetime Achievement Award
Brian G.M. Durie Outstanding Achievement Award
Ways to Give
Ways to Give
Major Giving
Monthly and Annual Giving
Matching Gifts
Planned Giving
Corporate Giving
Stock/IRA Donation
Create a Tribute
Other Ways to Give
Community Fundraising
Iceland Cycling Expedition
Run/Walk Events
Vehicle Donation
End of Year Giving
Be An Advocate
U.S. Advocacy
Global Advocacy (GMAN)
Global Myeloma Action Network (GMAN) Annual Summit
Multiple Myeloma: International Bill of Rights
EU Drug Approval and Reimbursement Policy
Veterans Against Myeloma
Myeloma Action Month
Blood Cancer Awareness Month
About Us
News
Events
Blogs
Advocacy
Fundraise
Donate Now
What is multiple myeloma?
Start Here
Learn more about multiple myeloma
Visit Our Library
No matter the situation, we are here for you
How can we help
The fight against myeloma starts here
The Road to the Cure
Your donation brings us closer to a cure
How Your Gift Helps
Donate
Myeloma Minute
Ask Dr. Durie
May 26
Should myeloma patients switch to the generic forms of medications?
Week in Review
April 14
Lower Cost Revlimid: Generic Lenalidomide is Here
Ask Dr. Durie
April 14
Is a generic version of Revlimid available?
ASCO/EHA
July 14
Final Analysis of the Phase 3 TOURMALINE-MM1 Study Investigating Ixazomib + Lenalidomide-Dexamethasone Vs Placebo-Rd in Relapsed Refractory Multiple Myeloma
ASCO/EHA
July 1
Overall Survival Results with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study
ASCO/EHA
June 9
Upfront autologous stem cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with K maintenance in transplant-eligible, newly diagnosed multiple myeloma
ASCO/EHA
June 9
Carfilzomib-based induction with or without ASCT followed by lenalidomide or carfilzomib-lenalidomide maintenance: Efficacy in high-risk patients
Ask Dr. Durie
May 27
COVID-19 FAQ #12: If a myeloma patient takes Revlimid (lenalidomide) as maintenance treatment, should this patient continue with that treatment during the pandemic?
Week in Review
October 31
What Is the Best Approach for Patients with Smoldering Myeloma?
Week in Review
July 18
Cancer prevention back in the news
Ask Dr. Durie
July 18
What does it mean to be refractory to Revlimid?
ASCO/EHA
June 3
E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma
Pagination
Previous page
‹‹
Page 2
Next page
››
Subscribe to lenalidomide
Give Where Most Needed
$25
$50
$100
$150
$250
Other
Learn More
